Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.2174/1574888X15999200729161539 http://scihub22266oqcxt.onion/10.2174/1574888X15999200729161539 32729428!ä!32729428 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 251.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Curr+Stem+Cell+Res+Ther 2021 ; 16 (3): 277-285 Nephropedia Template TP {{tp|p=32729428|t=2021. The Promise of Mesenchymal Stem Cells Therapy for Acute Respiratory Distress Syndrome Caused by COVID-19 |pdf=|usr=}}{{32729428}} gab.com Text The Promise of Mesenchymal Stem Cells Therapy for Acute Respiratory Distress Syndrome Caused by COVID-19 JO: Curr Stem Cell Res Ther http://www.kidney.de/pget.php?&tw=1&pmid=32729428 #FOAvip The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) since Dec 2019, known as COVID-19 or 19-nCoV, has led to a major concern of the potential for not only an epidemic but a pandemic in China and now it seems to be a public health problem all over the world. The general mortality rate of the COVID-19 was about 3%. However, the mortality risk seems to be a significant increase in elderly and cases with chronic disease, who are more likely to develop into acute respiratory distress syndrome (ARDS). There still lacks effective methods for ARDS of COVID-19 patients and the prognosis was poor. Mesenchymal Stem Cells (MSCs) based treatment has the advantage of targeting numerous pathophysiological components of ARDS by secreting a series of cell factors, exerting anti-inflammatory, antioxidative, immunomodulatory, antiapoptotic, and proangiogenic effects, resulting in significant structural and functional recovery following ARDS in various preclinical models. Recently, pilot clinical studies indicated MSCs based therapy was promise in treatment of ARDS caused by SARS-CoV-2. However, little is known about MSCs therapy for ARDS caused by COVID-19. Twit Text FOAVip The Promise of Mesenchymal Stem Cells Therapy for Acute Respiratory Distress Syndrome Caused by COVID-19 ????Curr Stem Cell Res Ther http://www.kidney.de/pget.php?&tw=1&pmid=32729428 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32729428 #FOAvip English Wikipedia <ref>{{Cite pmid|32729428}}</ref> The Promise of Mesenchymal Stem Cells Therapy for Acute Respiratory Distress Syndrome Caused by COVID-19 #MMPMID32729428 Gu J; Zhao Q; Han Z; Han Z Curr Stem Cell Res Ther 2021[]; 16 (3): 277-285 PMID32729428show ga The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) since Dec 2019, known as COVID-19 or 19-nCoV, has led to a major concern of the potential for not only an epidemic but a pandemic in China and now it seems to be a public health problem all over the world. The general mortality rate of the COVID-19 was about 3%. However, the mortality risk seems to be a significant increase in elderly and cases with chronic disease, who are more likely to develop into acute respiratory distress syndrome (ARDS). There still lacks effective methods for ARDS of COVID-19 patients and the prognosis was poor. Mesenchymal Stem Cells (MSCs) based treatment has the advantage of targeting numerous pathophysiological components of ARDS by secreting a series of cell factors, exerting anti-inflammatory, antioxidative, immunomodulatory, antiapoptotic, and proangiogenic effects, resulting in significant structural and functional recovery following ARDS in various preclinical models. Recently, pilot clinical studies indicated MSCs based therapy was promise in treatment of ARDS caused by SARS-CoV-2. However, little is known about MSCs therapy for ARDS caused by COVID-19. |Aged[MESH] |COVID-19/mortality/*therapy[MESH] |Cytokine Release Syndrome/mortality/*therapy[MESH] |Female[MESH] |Humans[MESH] |Immunomodulation/immunology[MESH] |Mesenchymal Stem Cell Transplantation/*methods[MESH] |Mesenchymal Stem Cells[MESH] |Respiratory Distress Syndrome/mortality/*therapy[MESH]The Promise of Mesenchymal Stem Cells Therapy for Acute Respiratory Di(epmc).pdf DeepDyve Pubget Overpricing